Over the last decades, vaccine development has advanced significantly in pursuing higher
safety with less side effects. However, this is often accompanied by a reduction in vaccine …

In this review we discuss recent progress in the development, testing, and clinical evaluation
of new vaccines against tuberculosis (TB). Over the last 20 years, tremendous progress has …

Successful vaccination against intracellular pathogens requires the generation of cellular
immune responses. Trehalose-6, 6-dibehenate (TDB), the synthetic analog of the …

Macrophages are a highly adaptive population of innate immune cells. Polarization with
IFNγ and LPS into the 'classically activated'M1 macrophage enhances pro-inflammatory and …

Background The current vaccine against tuberculosis (TB), BCG, has failed to control TB
worldwide and the protective efficacy is moreover limited to 10–15 years. A vaccine that …

Mincle is a C-type lectin receptor that has emerged as an important player in innate
immunity through its capacity to recognize a wide range of lipidic species derived from …

It is known that T cells can eliminate tumour cells through recognition of unique or aberrantly
expressed antigens presented as peptide epitopes by major histocompatibility complex …

The quest for a vaccine that could have a major impact in reducing the current global burden
of TB disease in humans continues to be extremely challenging. Significant gaps in our …

Tuberculosis (Tb) continues to be a dreadful infection worldwide with nearly 1.5 million
deaths in 2013. Furthermore multi/extensively drug-resistant Tb (MDR/XDR-Tb) worsens the …

Background one of the World Health Organization Millennium Development Goal is to
reduce tuberculosis incidence by 2015. However, more of 8.5 million tuberculosis cases …